Gleason 3+4 Prostate Cancer Treatment Options

Introduction to Treatment

The American College of Cardiology is not relevant here, however, the National Comprehensive Cancer Network recommends radical prostatectomy with pelvic lymph node dissection or external beam radiation therapy (minimum 70 Gy) with or without 4-6 months of androgen deprivation therapy for Gleason 3+4 prostate cancer, with the choice depending primarily on life expectancy and patient preference after counseling about treatment-related morbidity 1, 2

Gleason 3+4 prostate cancer is classified as intermediate-risk disease by all major guideline societies, including the National Comprehensive Cancer Network 1, 2, 3
Intermediate risk is defined as Gleason score 7, or PSA 10-20 ng/mL, or clinical stage T2b-T2c 3, 1, 2

Before treatment selection, complete staging evaluation should include cross-sectional imaging (CT or MRI of abdomen and pelvis) to evaluate for lymph node involvement, bone scan if PSA >10 ng/mL or if symptomatic, PSA measurement and digital rectal examination, and calculate predicted probability of lymph node involvement using nomograms 1, 2, 4, 5

For life expectancy <10 years, observation (watchful waiting) is the recommended approach, involving monitoring without immediate curative intent, PSA measurement and digital rectal examination at regular intervals, and delayed hormone therapy only if symptomatic progression occurs 3, 2, 4, 6
For life expectancy ≥10 years, standard curative treatment options include radical prostatectomy with pelvic lymph node dissection, external beam radiation therapy with or without androgen deprivation therapy, and brachytherapy alone for favorable intermediate-risk patients 3, 1, 2, 6

Pelvic lymph node dissection should be performed if predicted probability of lymph node involvement is ≥2% 3, 1
Lymphadenectomy should be limited to ilio-obturator regions 5
Expected outcomes include PSA should be undetectable (<0.2 ng/mL) within 2 months, and counseling required regarding permanent erectile dysfunction and urinary incontinence (should be <5% requiring >2 pads daily at 1 year) 2, 4, 7

Minimum dose of 70 Gy using 3D conformal techniques in 2.0 Gy fractions, with or without androgen deprivation therapy for 4-6 months 6, 2, 3, 1
Expected outcomes include PSA should reach ≤1.0 ng/mL within 16 months, and severe late complications (bladder/rectal) should be <5% at 2 years 6, 2, 7

Consider adding 4-6 months of androgen deprivation therapy to radiation therapy if multiple intermediate-risk factors present, higher PSA within the 10-20 ng/mL range, greater tumor volume on biopsy, or patient preference after counseling about sexual dysfunction risks 3, 1, 2
Perform pelvic lymph node dissection at radical prostatectomy if predicted probability of lymph node involvement ≥2% by nomogram, or may be omitted only if stage T1, Gleason score <6, and PSA <10 ng/mL 3, 5, 2

Patients must consult with both a urologist and radiation oncologist before making treatment decisions, including counseling about treatment-related adverse effects, expected recovery timelines, impact on quality of life, and salvage treatment options if initial therapy fails 1, 2, 4

After radical prostatectomy, PSA every 3 months during year 1, then every 6 months for 7 years, digital rectal examination optional if PSA remains undetectable, and biochemical recurrence defined as PSA ≥0.2 ng/mL on two consecutive measurements 4, 1
After radiation therapy, PSA every 6 months for first 5 years, then annually, biochemical recurrence defined as PSA rise ≥2 ng/mL above nadir, and consider salvage radiation to prostate bed if PSA rises after surgery (best outcomes when PSA <0.5 ng/mL) 1, 4